摘要
目的:探讨多药耐药基因(MDR1)在上皮性卵巢癌组织中的表达及临床意义。方法:采用逆转录-聚合酶链反应(RT-PCR)测定了37例上皮性卵巢癌,32例卵巢上皮性良性肿瘤和30例正常卵巢组织中MDR1的表达,并分析其临床意义。结果:正常卵巢组织不表达MDR1基因,卵巢良性肿瘤组织MDR1基因表达率为15.6%,上皮性卵巢癌组织表达率为75.7%。上皮性卵巢癌组织中MDR1基因表达与卵巢良性肿瘤相比较,差异有统计学意义(P<0.01)。化疗无效者MDR1的阳性表达率是94.1%,明显高于化疗有效者的57.1%(P<0.05)。结论:MDR1在上皮性卵巢癌组织中的表达高于正常卵巢组织及卵巢良性肿瘤,并与化疗疗效有关。
Objective To study the expression of multidrug resistance, and clinical significance of multidrug resistance gene expression in epithelial ovarian cancer. Methods RT-PCR was used to determine the expression of multidrug resistance in 37 cases of epithelial ovarian cancer, 32 cases of benign tumor and 30 cases of normal ovarian tissue. The expression rate of multidrug resistance and the clinical significance was explored. Results The expression rate of multidrug resistance gene in malignant, benign tumor and normal tissue of ovary was 75.7%, 15.6% and 0 respectively. The level of multidrug resistance gene expression in epithelial ovarian cancer was obviously higher than that in benign tumor（P〈0. 01）. The non-responders to combination chemotherapy exhibited higher rations of multidrug resistance expression than the responders （P〈0. 05）. Conclusion The expression of multidrug resistance is higher in epithelial ovarian cancer than that in normal ovary tissue and benign tumor. The expression of multidrug resistance is closely related to the tumor response to chemotherapy.
出处
《实用诊断与治疗杂志》
2007年第7期515-516,519,561,共4页
Journal of Practical Diagnosis and Therapy
